NOVARTIS SANDOSTATIN LAR APPROVED IN JAPAN FOR ACROMEGALY.

From: Worldwide Biotech | Date: June 1, 2004 | Copyright information

Novartis, Basel, Switzerland, has announced that the Japanese health authority has approved Sandostatin LAR (octreotide acetate for injectable suspension) for the treatment of acromegaly and pituitary gigantism which is unresponsive to or unsuitable for surgery or other drug therapies, and for symptoms associated with gastrointestinal hormone secreting tumors (also known as gastroenteropancreatic (GEP) neuroendocrine tumors (NET), including carcinoid tumors, gastrinomas, and VIPoma...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Event Brief of Novartis Corporation -Discussion on Novartis Oncology at American Society of Clinical Oncology (ASCO)- Conference Call - Final
Fair Disclosure Wire ; ... indications. 3. In Japan, NVS is launching ... are already approved. 2. To move ... chelator, was approved broadly in ... effects. 4. Now approved in 24 countries ... Exjade is approved in that part ... world. 6. Sandostatin LAR: 1. NVS reports ... SOM230. 3. Sandostatin is the ...
Novartis Corporation -Discussion on Novartis Oncology at American Society of Clinical Oncology (ASCO)- Conference Call - Final
Fair Disclosure Wire ; ... Right now, Novartis is running ... right now in Japan and France ... indications. In Japan, we're launching ... presence in Japan for Femara ... are already approved; second ... chelator, was approved broadly in ... it is now approved in 24 countries ... Exjade is approved in that ...